z-logo
open-access-imgOpen Access
Relapses of urogenital tuberculosis
Author(s) -
Е. В. Кульчавеня,
S. Yu. Shevchenko,
D P Kholtobin,
А А Баранчукова
Publication year - 2020
Publication title -
tuberkulez i bolezni lëgkih/tuberkulëz i bolezni lëgkih
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.226
H-Index - 12
eISSN - 2542-1506
pISSN - 2075-1230
DOI - 10.21292/2075-1230-2020-98-10-19-22
Subject(s) - tuberculosis , medicine , genitourinary system , isoniazid , urogenital tuberculosis , streptomycin , urinary system , surgery , antibiotics , pathology , microbiology and biotechnology , biology
The objective of the study: to characterize the cases of tuberculosis relapses with lesion in urogenital organs. Subjects and methods. Out of 140 case histories of patients with urogenital tuberculosis (UGTB; tuberculosis of the urinary and male reproductive system), registered for follow-up by the phthisiourologist, all files of patients with tuberculosis relapses were picked up, totally, there were 13 of them. Results. Men prevailed among cases of relapses (61.5%). Patients at the age of 30-50 years old made 46.1%, and 53.9% were 51 years old and above. In the first episode of tuberculosis, lesions of the genitourinary system were observed in 53.9% of patients, bacterial excretion was found in 38.5%. On the average, the relapse developed in 9.1 years after successful cure of the first episode of tuberculosis: after respiratory tuberculosis – in 5.6 years and after UGTB – in 12.3 years. In 3 (23.1%) patients with relapse, mycobacteriuria was documented, in 1 of them, drug resistance (to streptomycin and isoniazid) was detected. In general, in the relapse of tuberculosis with urogenital lesions, the kidneys were most often (69.2%) affected. The treatment of relapse was effective in 12 out of 13 patients. During chemotherapy of tuberculosis, 3 (23.1%) patients developed toxic and allergic reactions that required treatment interruption or cancellation of the drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here